Targeting the delivery of cytotoxic agents to tumour cells using novel minicells as drug delivery vehicles and engineered, bispecific antibodies

使用新型微细胞作为药物输送载体和工程化双特异性抗体，将细胞毒剂靶向输送至肿瘤细胞

• 批准号: LP110200126
• 负责人: Em/Prof Stephen Mahler
• 金额: $ 25.2万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Linkage Projects
• 财政年份: 2012
• 资助国家: 澳大利亚
• 起止时间: 2012-05-03 至 2015-05-02
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/LP110200126
• 关键词: Targeting; delivery; cytotoxic; agents; tumour

Cancer persists as a major cause of morbidity and mortality globally. A major problem is the non-specific action of drugs used for treatment. The minicell is a drug delivery vehicle, capable of packaging a variety of drugs. The project will develop tumour-specific antibodies that will target minicells to tumours, improving cancer survival rates.

癌症一直是全球发病率和死亡率的主要原因。 一个主要问题是用于治疗的药物的非特异性作用。 微细胞是一种药物递送载体，能够包装各种药物。 该项目将开发肿瘤特异性抗体，将靶向肿瘤的微细胞，提高癌症存活率。